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Summary 
We have assessed during B cell development, the regulation and function of bcl-x,  a member of 
the bcl-2 family of apoptosis regulatory genes. Here we show that Bcl-xr, a product of bd-x, is 
expressed in pre-B cells but downregulated at the immature and mature stages of B cell devel- 
opment. Bcl-xr but not Bcl-2 is rapidly induced in peripheral B  cells upon surface immuno- 
globulin M  (IgM)  cross-linking,  CD40  signaling,  or LPS stimulation.  Transgenic mice that 
overexpressed Bcl-xt within the B cell lineage exhibited marked accumulation of peripheral B 
cells in lymphoid organs and enhanced survival of developing and mature B  cells. B  cell sur- 
vival was  further increased by simultaneous  expression of bcl-xL  and  bcl-2  transgenes.  These 
studies demonstrate that Bcl-2 and Bcl-x  t  are regulated differentially during B  cell develop- 
ment and activation of mature B cells. Induction of Bcl-XL after signaling through surface IgM 
and CD40 appears to provide mature B  cells with an additional protective mechanism against 
apoptotic signals associated with antigen-induced activation and proliferation. 
N 
'aturally occurring cell death is common during B cell 
maturation and is accomplished by apoptosis, a mor- 
phologically defined process that is widespread during em- 
bryogenesis and postnatal development (1). During B lym- 
phocyte differentiation, it is  estimated that as  few as  one 
tenth of the daily 3-5 ￿  107 newly formed B cells is incor- 
porated into the peripheral mature pool (2,  3).  Death ap- 
pears to be the fate of most B cell precursors with the ma- 
jority of the cell loss  occurring during the transition from 
large, cytoplasmic ~  chain-producing B  cell precursors to 
small pre-B cells (4, 5). Because rearrangement of Ig genes 
is a stochastic process, many B  cell precursors fail to com- 
plete successful  assembly of H and L Ig chains and appear to 
undergo cell death in the bone marrow (BM) 1 (4, 5). Later 
in development, IgM+IgD -  immature B cells undergo fur- 
ther selection based on the specificity of their IgM surface 
receptors. Newly formed B  cells  that  recognize self-anti- 
gens are eliminated by apoptosis in the BM or are function- 
~Abbreviations used in this  paper: BM, bone marrow; CD40L, CD40 ligand; 
HIKP, horseradish  peroxidase; MCF, mean channel fluorescence. 
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ally inactivated (6). In the periphery, IgM+IgD + mature B 
cells  can undergo T  cell-dependent affinity maturation of 
their surface antigen receptors after encounter with  anti- 
gen. This process involves a high rate of somatic mutations 
in the rearranged Ig genes during antigen-induced prolifer- 
ation  in  germinal  centers  (7).  Mature  B  cells  exhibiting 
high affinity for antigen are preferentially selected whereas 
those displaying low affinity for antigen die by apoptosis (8, 9). 
The intracellular mechanisms that implement and regu- 
late apoptosis are still poorly understood, but it is thought 
that cell death is controlled by a genetic program induced 
within the dying cell (1,  10-12). Little is known about the 
signals that regulate developmental cell death in the B cell 
lineage. Because the selection of B cell precursors is largely 
based on the production of functional H  and L chain Ig re- 
ceptors, it has  been hypothesized that failure to express a 
pre-B  cell receptor complex leads  to  cell death  (13-15). 
Later  in  development,  signaling  through  surface  IgM  is 
critical for the elimination of B  cells activated by self-anti- 
gens in the BM, whereas the Fas receptor appears to play a 
major role in the deletion of activated B cells in the periph- 
ery  (16).  Beyond those  signals  that  regulate B  cell death 
during development, apoptosis can be induced in B  lym- 
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cytotoxic drugs, ~-irradiation, glucocorticoids, or withdrawal 
of growth factors (17-19). 
The bd-2 protooncogene was the first member of an ex- 
panding family of genes that suppresses the apoptotic mecha- 
nism  (20),  Enforced  expression of bd-2  in  lymphoid cells 
prevents  or  delays  apoptosis  induced  by  multiple  stimuli 
(17,  18, 21). A  role for Bcl-2 in the selection ofB lympho- 
cytes was  suggested by its pattern  of expression during B 
cell development (22, 23). Analysis of Bcl-2-deficient mice 
has demonstrated that Bcl-2 is essential for the maintenance 
of mature B  and T  lymphocytes (24, 25). In addition, Bcl-2 
appears to function as a survival signal for positive selection 
of B  cells in  germinal  centers  (8)  and  for  recruitment  or 
maintenance of high affinity memory B  cells (26, 27). 
Because mice deficient in Bcl-2 exhibited normal matu- 
ration of the B  cell lineage (24,  25),  we hypothesized that 
genes  other  than  bd-2  could  function  as  survival  signals 
during the selection and maturation of B  cell precursors. A 
candidate is bd-x,  a member of the bcl-2 family of apoptosis- 
regulatory genes. In the human,  two distinct bd-x mRNAs 
(bcl-xL  and bcl-xs)  that  encode proteins with  different bio- 
logical function were identified (28). In the mouse, bcl-x  L is 
the  dominant  bcl-x  mRNA  expressed  in  embryonic  and 
postnatal  tissues  including  primary  lymphoid  organs  (29, 
30).  Like Bcl-2,  the  product  of bcl-XL localized to  mito- 
chondria and perinuclear envelope (29) and can inhibit the 
apoptotic  death  of hematopoietic  cell  lines  after  growth. 
factor withdrawal (28). Analyses of Bcl-x-deficient  chimeric 
mice demonstrated significant alteration in the maturation 
of B  and  T  cell precursors  (31).  However,  the  biological 
basis for the altered phenotype observed during B  cell mat- 
uration  in  bcl-x  mutant  mice  was  unclear.  In  the  present 
studies,  we  sought  to  determine  the  regulation and  func- 
tion of bcl-x during B  cell developmenc 
Our results indicate that the  expression of Bcl-XL is es- 
sentially limited to pre-B cells, a narrow stage of develop- 
ment  characterized by extensive clonal selection.  In  con- 
trast, its functional homologue, Bcl-2, was  downregulated 
in pre-B  cells but  expressed in  pro-B  and  mature  B  cells 
(23).  Constitutive expression of Bcl-xr promoted accumu- 
lation of B  cell precursors and mature B  cells in the animal 
and enhanced B  cell survival in vitro. Our results demon- 
strate that Bcl-xL, but not Bcl-2, was upregulated after sur- 
face  IgM  cross-linking,  CD40  signaling,  or  LPS  stimula- 
tion.  Given  that  Bcl-2  and  Bcl-x  t  were  coexpressed  in 
mature  B  cells after activation, we  examined the  effect of 
simultaneous expression of bcl-2  and bcl-xL transgenes. Ex- 
pression of both Bcl-2 and Bcl-XL led to the enhanced ac- 
cumulation of B  cells in the animal and increased the pro- 
tection  against  anti-IgD-induced cell  death  in  vivo.  The 
implications of these findings for physiological pathways of 
B  cell development and survival are discussed. 
Materials and Methods 
Mice and Injections.  C57BL/6  mice were obtained from The 
Jackson  Laboratory (Bar  Harbor,  ME).  Animals used  for  these 
studies were between 8 and 12 wk of age unless  otherwise indi- 
cated. The Ig-bcl-2 transgenic mice (32) were a gift from Dr.  S. 
Korsmeyer (Washington University, St. Louis, MO). Mice were 
bred and maintained in a pathogen-free environment at the Uni- 
versity of Michigan Animal Facilities. To study the effects ofdexa- 
methasone  on BM B  cell populations, animals received a single 
i.p. injection of 2 mg ofdexamethasone (American Regent Labo- 
ratories, Shirley, NY)  or PBS as control. BM cells from two fe- 
murs were harvested 48  h  later and stained as described below. 
To analyze the effect ofanti-IgD treatment on B cell populations, 
mice were treated according to the following schedule (33): 3 mg 
ofanti-IL-7 mAb (M25 clone; 34) injected intraperitoneally three 
times per week starting 2 wk before injection of anti-IgD anti- 
body and continuing for 1 wk;  1 mg ofanti-CD4 mAb (GK1.5 
clone; 35)  once a week injected intravenously starting 2 wk be- 
fore injection of anti-lgD antibody and continuing for  1 wk;  1 
mg of anti-Fc3,RII mAb (24G2 clone; 36) injected intravenously 
along with the injection of anti-IgD antibody; 1 mg of anti-IgD 
mAb (HB86 clone; 37) injected 1 wk before killing. The number 
of BM and peripheral B cell populations was determined by flow 
cytometry as described below. To assess the efficiency ofanti-Igl) 
treatment, the expression of IgD on B cells was analyzed by flow 
cytometric analysis 2 d after injection ofanti-IgD mAb. After this 
treatment, IgD molecules were saturated to the same extent in all 
groups of mice (data not shown). 
Construction  of  SV40-Elz-bcl-xL  Transgene  and  Generation  of 
Transgenic Mice.  To target bcl-xL to the lymphoid compartment, 
the human bcl-x  L eDNA was cloned under the regulatory control 
of the SV40  promoter and IgH enhancer using a SV40-EH  cas- 
sette (21).  The 2.4-kb fragment containing the SV40-EH-bcl-x~. 
insert was microinjected into F  2 hybrid zygotes from (C57BL/6  ￿ 
SJL/J)F  l parents at a concentration of 2-3 ng/txl. After overnight 
incubation, the eggs that survived to a two-cell stage were trans- 
ferred to day 0.5 postcoitum pseudopregnant CS-1 females.  3 wk 
after birth, genomic DNA was prepared from tail tissue  and the 
incorporation of the human bcl-x  L transgene was assessed by dot 
blot analysis or by PCR as previously described (28). 
Cell Preparations.  B  cell-enriched populations were  purified 
from spleens of normal and transgenic mice after in vitro treat- 
ment with anti-Thy-l.2 mAb (HO-13.4 clone, a rat IgM anti- 
mouse Thy-l.2 mAb) and complement (Cedarlane Laboratories, 
Ltd., Hornby, ON, Canada). The resulting cell populations were 
>90% slgM  + and <1% CD4 + or CD8 +. To analyze the expres- 
sion of Bcl-x or Bcl-2 after B  cell activation in normal mice, B 
cell-enriched spleen cells were cultured in RPMI supplemented 
with 2 mM L-glutamine, 10 -5 M  2-MER, and 10% heat-inacti- 
vated FCS (Hyclone Laboratories, Logan, UT) at a concentration 
of 5 ￿  106 cells/ml in the presence of different concentrations of 
affinity-purified F(ab')2 goat anti-mouse IgM polyclonal antibody 
(Jackson  ImmunoResearch Laboratories, Inc., West Grove, PA), 
1  b~g/ml  recombinant  CD40L  (38),  or  10  ~g/ml  LPS  (Sigma 
Chemical Co., St. Louis, MO). At several time points, cells were 
harvested, washed twice in PBS,  and cell lysates prepared as de- 
scribed below.  Protein concentration in lysates  was  determined 
using a protein detection kit  (Pierce Chemical Co.,  Rockford, 
IL). For cell viability assays, B cell-enriched spleen cells were cul- 
tured in triplicate at a concentration of 106  cells/ml in  96-well 
microtiter plates. Viable cells were determined at different days by 
trypan blue exclusion. 
Antibodies.  FITC-labeled anti-CD4 (clone H129.19) and PE- 
conjugated anti-CD8 (clone 53-6.7) mAbs were purchased from 
GIBCO  BRL  Research  Laboratories (Gaithersburg, MD).  The 
following antibodies were  obtained from  PharMingen  (San Di- 
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PE-conjugated anti-CD45R  (B220)  (clone RA3-6B2), PE-con- 
jugated anti-CD24 (HSA) (clone M1/69), PE- and FITC-labeled 
anti-IgM (clone R6-60.2),  FITC-labeled anti-IgD  b (clone 217- 
170),  and FITC-labeled anti-CD43 (leukosialin) (clone $7).  The 
streptavidin-RED670  TM reagent was bought from GIBCO-BRL 
Research Laboratories. 
Flow Cytometric  Analysis.  Single cell suspensions from spleen, 
LN,  and BM were prepared as previously described (39).  Cells 
(106  )  were  incubated with  different combinations of antibodies 
specific for cell surface markers in 100 b~l ofPBS-I% BSA for 30 
min  on  ice and washed  twice with  PBS-I% BSA. When  indi- 
cated, streptavidin-IkED670  TM was used for three-color analysis. 
Cells were analyzed with a FACScan  |  flow cytometer and a min- 
imum of 3  ￿  104 events per sample was counted using Lysys II 
software (Becton Dickinson & Co., Mountain View, CA). Anal- 
ysis of Bcl-x expression in B  cell progenitors was performed by 
flow  cytometry as previously described for Bcl-2  (23),  using a 
mouse  IgG3 anti-Bcl-x mAb  (40)  followed by a  biotin-conju- 
gated  goat  anti-mouse  IgG3  (Caltag  Laboratories,  South  San 
Francisco, CA) and streptavidin-RED670  TM. 
Western Blot  Analysis.  Bcl-x  L or Bcl-2 expression was deter- 
mined  by  Western  blot  analysis  as  previously  described  (23). 
Briefly, proteins (25-100  Ixg/sample) were transferred to  nitro- 
cellulose  membranes  by  electrophoresis and  then  incubated  at 
4~  overnight with a rabbit anti-Bcl-x polyclonal serum (41) di- 
luted 1/500, 4Cll, a rat anti-mouse Bcl-2 (42), or with a mouse 
anti-~-Tubulin antibody (Sigma Chemical  Co.)  in  1.5%  milk- 
TBS  (Tris-but}?red saline)  with  30  Ixl  of normal  goat  serum 
(Sigma Chemical Co.) After five washes in TBS with 0.05%  of 
Tween 20, the membrane was incubated for 1 h at room temper- 
ature with horseradish peroxidase (HRP)-conjugated goat anti- 
rabbit, goat anti-rat, or goat anti-mouse antibodies (Jackson  Im- 
munoResearch Laboratories, Inc.) diluted 1/50,000 in 1.5% milk- 
TBS.  The  reaction was  developed by enhanced  chemilumines- 
cence using the ECL kit (Amersham Corp., Arlington Heights, IL). 
Results 
Bd-xL Expression Is Highly Regulated during B  Cell Devel- 
opment in Normal Mice.  The  expression  of Bcl-x  proteins 
was  assessed  in  developing and  mature  B  cells  by  three- 
color flow cytometric analysis using different combinations 
of antibodies  directed  to  specific  surface  markers  and  a 
mouse  anti-Bcl-x mAb  (40).  The  Bcl-x protein  was  de- 
tected at very low levels in B220a"nCD43 + pro-B cells, up- 
regulated in  IgM-B220  a~" pre-B cells, and downregulated 
again in IgM+HSA  high immature B  cells (Fig. 1).  Bcl-x was 
not  detected in  mature B  cells from  spleen  (Fig.  1).  This 
difference in.Bcl-x expression was quantified by calculating 
the ratio of mean  channel fluorescence (MCF)  of Bcl-x to 
MCF of control Ig in each subpopulation. The MCF ratio 
for pro-B  cells was  1.6  --  0.3,  increased to  3.0  -+-  0.2  for 
pre-B cells and decreased again for immature B cells to 1.7  -+ 
0.2.  For mature B  cells from the BM and spleen, the ratio 
was 1.1  -+ 0.2. To confirm these observations and to deter- 
mine  which  form  of Bcl-x  was  expressed, populations  of 
BM B  cells enriched in B220+IgM -  (pro- and pre-B cells) 
and  B220+IgM +  (immature  and  mature  B  cells)  were 
sorted at high purity by flow cytometry and cell lysates an- 
alyzed by Western blot analysis. Bcl-XL was  the  only bcl-x 
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Figure 1.  Expression  of endogenous Bcl-x during B cell development. BM and spleen cells from 8-wk-old C57BL/6 mice were labeled with FITC- 
conjugated anti-lgM or anti-CD43, PE-conjugated anti-B220 or anti-HSA, or biotinylated anti-lgD antibodies. Cells were fixed with PBS containing 
2% paraformaldehyde, permeabilized with saponin, labeled with anti-Bcl-x mAb or isotype-matched control antibody, and analyzed by flow cytometry. 
(Top) Contour  plots  of BM  cells stained with  different  combinations  of mAbs. BM  cell populations were  determined  as  follows: pro-B cells 
(IgM-CD431~  pre-B and pro-B cells (lgM+B2201~  immature B cells (lgM+HSAhigh),  and mature cells (IgM+HSAI~  (Bottom) Intensity of Bcl- 
x staining (histogram b) in the B cell populations gated in the upper panels. Background staining with control mouse IgG3 is shown for comparison (his- 
togram a). Results are representative of three different experiments. 
383  Grillot et al. Figure 2.  Bcl-x  L is the bcl-x product expressed during B cell develop- 
ment.  B220+-IgM  -  and B220+-IgM  + B  cell populations were  sorted 
from BM by flow cytometry. The expression of Bcl-x in cell lysates  from 
these fractions (25 ~g of protein each lane) was assessed  by Western blot 
analysis using a polyclonal anti-Bcl-x antibody followed by HRP  goat 
anti-rabbit serum. 
product detected in preparations of developing and mature 
B  cells (Fig. 2). The 30-kD Bcl-xL protein was expressed in 
lysates from B220+IgM -  B  cell precursors but downregu- 
lated in  more  mature  B220+IgM +  B  cells  (Fig.  2).  These 
results  demonstrate  that  Bcl-xL  is  the  bcl-x  product  ex- 
pressed during B  cell development.  Furthermore,  the  ex- 
pression  pattern  of Bcl-xL  is  predominantly  restricted  to 
pre-B  and  differs  considerably  from  that  previously  re- 
ported for Bcl-2 (23, 43). 
Bcl-x  L but Not Bd-2 Is Induced in Mature B  Cells after Acti- 
vation.  Resting B  cells from  peripheral lymphoid tissues 
express Bcl-2 but are devoid of Bcl-x protein (23 and Fig. 
1). To assess whether Bcl-x is regulated during cellular acti- 
vation, purified populations of splenic B  cells were stimu- 
lated with purified F(ah)'  2 anti-IgM antibody or LPS, two 
signals  that  induce  activation  and  proliferation of B  cells 
(44).  Bcl-xL was  clearly upregnlated  by  6  h  and  reached 
maximum  expression at 24  h  after surface IgM cross-link- 
ing (Fig. 3 A). The Bcl-x product was detected as a doublet 
of 29-31  kD in agreement with previous reports  (41,  45). 
Induction of Bcl-xt with anti-IgM was dose dependent and 
reached  a  plateau  with  10  Ixg/ml  of anti-IgM  antibody 
(data not shown).  Similarly, stimulation of B  cells with the 
mitogen LPS upregulated Bcl-xL with kinetics comparable 
to that observed with anti-IgM (Fig. 3 B). Similarly, signaling 
through  CD40  using recombinant  CD40  ligand (CD40L) 
induced Bcl-x  L in  splenic B  cells  (Fig.  3  C).  The  level of 
Bcl-x  L induced by CD40  signaling was very similar to that 
observed after anti-IgM cross-linking (Fig. 3  C). Induction 
Figure 3.  Activation of mature B cells  with anti-lgM antibody, LPS, or 
CD40L induces Bcl-x  L  but not Bcl-2 expression. B cell enriched popula- 
tions were obtained from spleens of normal mice and stimulated in vitro 
with  10 p,g/nll of F(ab')2 goat anti-mouse  IgM polyclonal antibody (A 
and D), 10 txg/ml ofLPS (B), or 1 ~g/ml recombinant CD40L (C and 
D). After 3, 6, 12, 24, or 48 h of incubation, cells  were harvested and the 
expression of Bcl-x in cell lysates (50 p,g of protein in each lane) was as- 
sessed by Western blot analysis  using a polyclonal anti-Bcl-x antibody (A- 
C) or 4C11, a rat anti-Bcl-2 mAb (D) followed by HP,.P goat anti-rabbit 
or anti-rat serum. In C, the last lane represented a lysate from cells stimu- 
lated with anti-IgM antibody for 24 h to allow comparison  between Bcl-x 
and Bcl-2 expression. In the experiment shown in C, activation of B cells 
with anti-IgM  and CD40L was performed in parallel. Activation of B 
cells with LPS (B) was performed in a separate experiment. 
of Bcl-xL  with  anti-IgM  or  CD40L  was  specific  in  that 
both B  cell activators failed to  modulate Bcl-2  expression 
(Fig. 3  D).  Thus,  peripheral B  cells that constitutively pro- 
duce Bcl-2 can be induced to express Bcl-xL after signaling 
through  surface  IgM  receptors,  stimulation  by  LPS,  or 
CD40. 
Generation  of Transgenic  Mice Expressing  Constitutively  Bcl- 
xL in the B  Cell Lineage.  We developed a transgenic mouse 
model to  assess  the  effects of Bcl-xL overexpression in the 
animal.  The  bd-xL  human  cDNA  was  placed  under  the 
control of the IgH enhancer (Fig. 4 A), which is known to 
target genes to lymphoid cells (21, 46). Three founder mice 
384  bd-x during B cell Development and Activation Figure 4.  Ep,-bcl-x  L transgene construct and Western 
blot analysis  of Bcl-x  L expression. (A) A 0.75-kb cDNA 
fragment containing the coding region of human bcl-x  L 
(closed box) was  inserted  into  the  EcoRl  site of the 
EI.tSV40 cassette (21). EI~ is the IgH enhancer and SV40 
the early SV40 promoter.  (B) Expression of Bcl-x  r was 
assessed by Western blot analysis  with a polyclonal anti- 
Bcl-x antibody followed by H1KP goat anti-rabbit serum. 
Lysates  from these cells (50 llg of  protein) were loaded in 
each lane. Lysates from  FL5.12 cells stably transfected 
with  the human  bcl-x  s, murine  bcl-x~, or murine  bcl-xl. 
cDNA (28, 29) are shown in the first three lanes, respec- 
tively, as positive controls and indicated as Bcl-x  L, Bcl-x~3 
and Bcl-x~. Notice that FL5.12 cells transfected with bcl- 
xs  and  bcl-x~ also expressed endogenous  Bcl-x  r.  (C) 
Comparison of Bcl-x  t  levels between  resting B splenic 
cells from transgenic and activated B cells  from control 
mice. B cells from normal mouse were activated for 24 h 
with  10  btg/ml of F(ab')2  goat anti-mouse  IgM poly- 
clonal antibody. Western blot was performed using ly- 
sates containing 100, 50, or 25 Ftg of total proteins. As a 
control, expression of [3-tubulin was also assessed  with a 
mouse antiq3-tubulin  antibody followed by goat anti- 
mouse serum conjugated to HRP.  Densitometry scan- 
ning showed that resting splenic B cells  from transgenic 
animals expressed  30% more Bcl-x  t than activated B cells 
from control mice. 
expressing Bcl-xr in lymphoid tissues were  identified and 
used to establish transgenic lines. Each hne was assessed for 
expression of Bcl-xr protein by Western blot analysis using 
a polyclonal antibody reactive with the murine and human 
Bcl-x proteins  (41).  One  line  (bcl-x-87)  that exhibited re- 
stricted  expression  of the  bcl-x  L  transgene  to  the  B  cell 
compartment was further characterized. As shown in Fig. 4 
B, Bcl-XL was the only bcl-x product detected by Western 
blot analysis in the BM and thymus of normal mice. Bcl-x  r 
protein was  overexpressed in the BM  of bcl-x-87  as com- 
pared to the levels of endogenous Bcl-XL in nontransgenic 
littermates (Fig. 4  B).  Moreover,  Bcl-x  L was  undetectable 
in the spleen and lymph nodes  of normal mice but it was 
expressed in  bcl-x-87  animals  (Fig.  4  B).  The  bcl-x  L trans- 
gene was not detected in purified populations ofT cells and 
in several nonlymphoid organs including brain, liver, kid- 
ney, and lung as determined by comparison to endogenous 
levels ofBcl-x  r  observed in control mice (data not shown). 
The  relative  levels  of Bcl-x  L in  activated  splenic  B  cells 
from normal mice and those in resting B  cells from trans- 
genic mice were  similar when  compared by Western blot 
analysis (Fig. 4  CO. 
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Bcl-x  L Protects Immature and Pre-B Cells against Dexametha- 
sone-induced  Cell Death.  Pre-B  and  immature  B  cells  are 
highly sensitive to treatment with glucocorticoids (23).  To 
assess the  effect of Bcl-xr overexpression in mice,  bcl-x-87 
transgenic and control httermate animals were treated with 
2 mg ofdexamethasone or PBS as a vehicle control, and 48 h 
later the different B  cell populations in the BM were quan- 
tiffed by flow cytometry. In accordance with previous results 
(23),  80% of IgM-B220  auu pre-B and 95%  IgM+IgD -  im- 
mature  B  cells  were  preferentially  depleted  after  dexa- 
methasone treatment (Table 1).  In contrast, pre-B and im- 
mature  B  cells from  bcl-x-87  transgenic mice were  largely 
protected  (Table  1).  For comparison,  parallel experiments 
were  performed  with  bcl-2  transgenic  mice  that  express 
Bcl-2  in  the  B  cell  lineage  (32).  As  previously reported, 
overexpression of Bcl-2 protects pre-B and immature B  cells 
against  dexamethasone-induced  cell  death  (21,  32,  47). 
These results indicate that Bcl-xr can protect developing B 
cells from glucocorticoid-induced death in a manner indis- 
tinguishable from that of Bcl-2 (Table 1). 
Bcl-x  L  Increases  the  Survival  of  Splenic  B  Cells  In  Vitro. 
Splenic B  cells, when cultured in vitro without growth fac- Table  1.  Overexpression of Bcl-x  L Protects Pre-B and Immature BM Cells against Dexamethasone (Dex)-induced  Cell Death In  Vivo 
Bone marrow B cell populations (￿  106)  * 
Mice  Dex  Total  B220 +  Pro-B  Pre-B  Immature  Mature 
Control  -  31  +_ 3.0  7.8 _+  1.7  1.4 -+ 0.2  3.3 +- 0.2*  1.3 _+ 0.2*  1.8 -+ 0.2* 
+  28 -+ 2.0  5.4 _+  1.5  1.0 -+ 0.2  0.7  -+ 0.2*  0.1  -+ 0.0'  3.6 -+ 0.6* 
bd-x-87  -  35 -+ 5.5  19.0 _+ 5.1  2.0 -+ 0.1  6.8  _+ 2.5*  3.9 _+ 0.5  6.3  +  0.6* 
+  36 +  4.6  19.8 _+ 5.2  1.2 -+ 0.2  4.0 --- 0.3*  4.6  _+ 0.5  9.9  +  1.9' 
Ig-bd-2  -  38 _+ 5.0  18.0 +  4.7  1.8 -+ 0.2  6.4 _+  1.3'  3.6 -+ 1.0  6.2 +- 1.0  r 
+  40 _+ 6.1  19.1  _+ 4.0  1.9 -+ 0.1  4.0 _+ 0.4*  4.0 +  0.4  9.2 -+ 1.5' 
*Results were obtained by three-color flow cytometric analysis  of BM cells from two femurs simultaneously  labeled with PE-conjugated anti-B2(~), 
biotinylated anti-IGD, and F1TC-conjugated  anti-IgM or anti-CD43. Cell populations were determined as follows: mature B cells (lgM+lgD*), im- 
mature B cells (IgM  +  IgD-), pre-B cells (IgM-B2201~  pro-B cells (IgM-B220J~176  Values represent the mean + SD for 10 15-wk- 
old animals. 
*  Cell number between control and transgenic  animals  were significantly  different (p <  0.01) as determined by the Student's t test. 
tors, rapidly begin to die by apoptosis (48). To assess the ef- 
fect of bd-xL  on B  cell survival, spleen cells from bcl-x-87 
transgenic and control littermates were cultured in tLPMI 
medium supplemented with  10%  FCS  and their viability 
assessed  by trypan blue exclusion from day 1 to  10.  There 
was  an improved survival of spleen cells from  transgenic 
mice  when  compared  to  spleen  cells  from  control mice 
(Fig.  5).  After  10  d  of culture, only 5%  of spleen B  cells 
from normal mice were viable whereas 40% of the B  cells 
from  bcl-x-87  mice survived (Fig.  5).  By comparison, we 
assessed  the  survival of spleen cells  from  bd-2  transgenic 
mice (32)  (Fig. 5). As previously reported, survival was sig- 
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Figure 5.  Expression  of the bd-xL transgene  increases  B cell viability  in 
vitro. Spleen cells were cultured in tripficates in 96-well flat-bottomed 
plates at a concentration of 106 cells/ml in 1LPMI 10% FCS. From day 1 
to  10, viability of spleen B cells was assessed by trypan blue exclusion. 
Results are representative of four separate experiments. Cells were ob- 
tained from bd-x-87 (D), bcl-2 (A), bd-x-87/bd-2 transgenic  mice (O), or 
control littermates (O). 
nificantly increased for splenic B  cells from bd-2 transgenic 
mice (21, 32) in a manner similar to that observed in bd-x- 
87 transgenic mice (Fig. 5). 
Resting mature B  cells constitutively express high levels 
of Bcl-2 (23)  but undetectable levels of Bcl-x  L (Figs.  1,  3, 
and 4 B). However, after activation, Bcl-xe was induced in 
splenic  B  cells  whereas  Bcl-2  expression  remained  un- 
changed  (Fig.  3).  To  determine whether  coexpression  of 
Bcl-2  and  Bcl-x  t  confers  an  increased  resistance  to  cell 
death, we compared the capacity of B  cells from bd-x-87/ 
bcI-2  double  transgenic mice,  bd-2  or  bcl-x  L  single trans- 
genic mice, and control littermates to survive in vitro. The 
viability of splenic B cells coexpressing bcl-x and bcl-2 trans- 
genes  was  significantly enhanced as  compared  to  that  of 
single bd-x or bcl-2 transgenic mice (Fig. 5). 
Constitutive  Expression  of Bcl-x  L Leads  to  Accumulation  of 
Developing and Mature B  Cells.  The  results  shown  above 
indicated  that  the  bd-xL  transgene  expressed  in  bd-x-87 
mice was functional in pre-B, immature B, and peripheral 
B cells (Table 1 and Fig. 5). We next assessed whether Bcl- 
xt overexpression affected B cell homeostasis. In 5-mo-old 
bcl-x-87  mice,  the  total  number of spleen  cells  was  in- 
creased by 108% (283 X  106 vs. 136 X  106 in control mice) 
and the  total  number of LN  cells was  increased by 92% 
(15.5  ￿  106 in bd-x-87 mice vs. 7.8 ￿  106 in control mice; 
Table  2).  This  increase  was  due  to  an  accumulation of 
B220 +  cells  in all  tissues  examined since the  number of 
CD4 +  and CD8 + T  cells remained practically unchanged 
(Table 2). In the BM, the total number of B220 + cells was 
increased by 158% (18.6  ￿  106 in bcl-x-87 mice vs. 7.2  ￿ 
106 in control mice). Although pre-B and immature B cells 
were significantly augmented in bcl-x-87 mice, the number 
of mature  IgM+IgD  +  B  cells  was  particularly  increased 
when compared to control littermates (Table 2). Given the 
distinct pattern of expression of Bcl-2 and Bcl-xr during B 
cell development, we compared the phenotype of bcl-x-87 
transgenic animals with that of bd-2 transgenic mice (32). It 
386  bcl-x during B cell Development and Activation Table 2.  Accumulation of Mature B Cells in bcl-x-87,  bd-2, and bd-x-87 /bd-2 Transgenic (tg) Animals 
Number of cells in mice (X  106) 
Cell populations  Control  bcl-x-87 tg  bcl-2 tg  bcl-x-87/bcl-2  tg 
BM*  33.0 +  1.9  34.7 +  3.5  36.7 -+- 2.4  52.0 -  5.011 
B220 + cells  7.2 +  0.5  18.6 +  2.89  18.9 +_  1.99  26.2 +  2.91 
Pro-B cells  1.5 +  0.2  2.0 +  0.29  1.9 +  0.2  2.1  •  0.211 
Pre-B cells  2.9 +  0.3  6.0 +  1.0S  6.2 +  0.8~  9.4 •  1.711 
Immature B cells  1.2 +  0.0  4.0 +  0.2~  4.3 +  0.4S  4.9 +  0.511 
Mature B cells  1.6 _+ 0.1  6.6 +  1.3~  6.5 +  1.69  9.8 +  2.011 
Spleens  156.0 ___ 10  263.0 --_ 15~  248.0 _  23~  328.0 •  4211 
B220 + cells  81  -•  7.1  184.0 +  129  171.0 _+ 169  227.0 --- 3511 
CD4 § cells  25.8 +  2.6  27.4 -  2.9  28.0 +  1.9  26.8 •  3.0 
CD8 + cells  20.9 •  3.1  20.4 •  1.9  20.6 --- 2.4  22.3 --- 2.5 
7.8 -  0.3  15.5 •  3.3~  17.5 •  2.0~  20.5 --- 0.51f 
B220  + cells  3.2 -  0.2  8.3 •  0.6~  8.8 --- 0.3~  12.0 --- 1.411 
CD4 + cells  2.5 --- 0.3  3.3 +  0.7  2.9 •  0.4  3.5 •  0.8 
CD8 § cells  1.6 -  0.1  1.8 +  0.3  1.8 +  0.1  1.7 •  0.2 
*Results were obtained by three-color flow cytometric analysis of BM cells from two femurs simultaneously labeled with FITC-conjugated anti- 
IgM or anti-CD43, PE-conjugated anti-HSA, and biotinylated anti-B220 antibodies.  Immature B cells were defined as IgM+HSAhighB2201~  ma- 
ture B cells as IgM+HSAL~  ~gh, pre-B cells as IgM-CD43-B220 low, and pro-B cells as IgM-CD431~  l~ 
~tAnalyses of cells from spleen and inguinal  and axillary LN were performed by simultaneously labehng with FITC-conjugated anti-CD4, PE-conju- 
gated anti-CD8, and biotinylated anti-CD3 antibodies. Values represent the mean +  SD for 10 15-wk-old animals. 
~. HValues between single transgenic and control littermates  or between double and single transgenic mice, respectively, were statistically different 
(p <0.01) as assessed by the Student's t test. 
is interesting to note that the phenotype and accumulation 
pattern  of B  cell populations in  the  BM,  LN,  and spleen 
were similar in bcl-x  L and bd-2 transgenic animals (Table 2). 
Because activated B  cells can express  both Bcl-2 and Bcl- 
xt, we tested the possibility of a functional interaction be- 
tween the two proteins in vivo by mating bcl-x-87 and bd-2 
transgenic  mice.  Co-expression  of both  bd-x  L  and  bcl-2 
transgenes resulted in a significant increase of mature B  cells 
in BM, spleen, and LN as compared to bcl-xL or bcl-2 trans- 
genic animals (Table 2). 
Combined  Overexpression  of Bcl-x  L  and  Bcl-2  Can  Protect 
against Anti-IgD-induced Cell Death In  Vivo.  Cross-linking  of 
membrane IgD on mature B  cells, in the absence of T  cell 
help, has been shown to result in B  cell death in vivo (33). 
The anti-IgD model was used to evaluate the ability of Bcl- 
x r  or Bcl-2 to block Ig receptor-mediated B  cell death in 
the  absence  of T  cell  costimulatory  function.  Transgenic 
(bcl-x-87,  bcl-2,  bclox-87/bd-2)  and  nontransgenic  mice 
were  treated  with anti-IL-7 mAb to block the  generation 
of newly formed B  cells (34), with anti-CD4 mAb to block 
the  generation of T  cell help  (49),  and with  anti-Fc'yRII 
mAb to avoid any potential inhibitory interactions between 
surface  Ig and  Fc~/IklI.  In both  bd-x L and/or  bcl-2  trans- 
genic mice and control littermates, treatment with anti-IL-7 
antibody induced a 90% reduction in the number of pre-B 
and  immature  B  cells,  indicating  that  overexpression  of 
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Bcl-2 and/or Bcl-xr proteins cannot overcome the inhibi- 
tory  effect  of anti-IL-7 mAb  on the  generation  of newly 
formed B  cells  (data not shown).  7  d  after  anti-IgD treat- 
ment, a decrease of 86  +  3% in the total number of IgM + 
mature B  cells was observed in nontransgenic animals (from 
81.5  ￿  106 to  11.2  ￿  106;  Fig.  6),  which is in agreement 
with recently published results (33).  It is interesting to note 
that overexpression of Bcl-xL or Bcl-2 had little or no ef- 
fect on anti-IgD-induced B  cell death (79  +  2% reduction 
for bcl-2 transgenic mice and 82 -+ 5% reduction for bd-x-87 
transgenic mice;  Fig.  6).  In contrast,  IgM +  mature  B  cells 
from double bcl-x-87/bd-2  transgenic animals were partially 
but  significantly  protected  from  anti-IgD-induced  cell 
death  when  compared  to  the  number of B  cells that  sur- 
vived in control, bcl-x-87,  or bcl-2 mice  (53  +  6% reduc- 
tion from 110.2  ￿  106 to 52.1  ￿  106). Thus, coexpression 
of Bcl-2 and Bcl-xe, but not Bcl-2 or Bcl-x  r alone, partially 
protected B  cells from death induced by surface IgD cross- 
linking with a high affinity anti-IgD antibody (33). 
Discussion 
These studies demonstrate that Bcl-x  L is developmentally 
regulated in the B  cell lineage and functions to protect de- 
veloping and mature B  cells from apoptosis. The pattern of 
Bcl-x  L expression is strikingly different from that of Bcl-2, Figure 6.  Protection of periph- 
eral B cells from anti-lgD-induced 
cell death by bcl-x-87/bd-2 trans- 
genes in  vivo.  2-mo-old control 
and transgenic bd-x-87, bd-2, and 
bd-x-87/bd-2  mice  were  treated 
with  anti-IL-7,  anti-CD4,  and 
anti-Fcyl<II mAbs and with  anti- 
IgD mAb (empty bars) or PBS (gray 
bars). The number of IgM  + mature 
B  cells in  the  spleen was  deter- 
mined by flow cytometric analysis 
using  FITC-conjugated  anti-lgM 
and  biotinylated  anti-B220  anti- 
bodies.  Data represent  the  mean 
values obtained  with  four  7  wk- 
old nfice +  SD. The reduction in 
the  number  of  IgM  +  mature  B 
cells between anti-IgD-treated and 
PBS-treated  animals  is  indicated 
for each group as a mean percent- 
age -+ SD. The number of mature 
B cells after anti-IgD treatment in bd-x-87/bd-2 mice was statistically  different when compared to the number of mature B cells in the other groups of 
mice (p <0.0l by Student's t test). Note that at 7 wk, bd-x-87, bd-2, and bd-x-87/bd-2 transgenic mice have not accumulated B cells in the spleen as 
much as the 15 wk-old mice shown in Table 2. 
a  functional homologue  of Bcl-x  L. Pre-B  cells, a  develop- 
mental  stage  in  which  Bcl-2  is  downregulated  (23),  ex- 
pressed the  highest levels of Bcl-x  L.  Although  the  role  of 
Bcl-xL during B  cell development is not fully understood, 
our studies argue that Bcl-x  L provides a  survival signal for 
the  maintenance  of pre-B  cells  and  activated  mature  B 
cells. Recent studies with chimeric mice have shown a dif- 
ferential defect in the maturation and survival ofpre-B cells 
deficient in Bcl-x without obvious alterations in mature B 
cells (31).  Our studies provide an explanation for the latter 
findings in that Bcl-XL is expressed predominantly in pre-B 
cells,  the  developmental  stage  particularly affected by the 
absence of Bcl-x (31).  Furthermore, transgenic mice over- 
expressing Bcl-x  L exhibited accumulation of immature and 
mature B  cells, implying that Bcl-x  L promotes the matura- 
tion ofpre-B cells into B  cells. Although a specific role for 
Bcl-x  L on B  cell differentiation is possible, the results sug- 
gest  that  Bcl-x  L acts  primarily by inhibiting  cell  death,  a 
function  that is  essential for  the  maturation  of pre-B  cells 
into mature B  ceils. 
Bcl-x  L and  Bcl-2  exhibit  a  distinct  expression  pattern 
implying that these two related proteins play different roles 
in B  cell selection and homeostasis. Bcl-2 but not Bcl-xL is 
highly  expressed  in  large  CD43 +  early B  cell  precursors 
that  undergo  extensive  rearrangements  of  IgH  and  IgL 
chain genes  (23).  Thus,  Bcl-2 may play a role in the initial 
stage  of B  cell maturation  when  a  diverse pool  of pre-B 
cells is generated through IgH and IgL gene recombination 
(14, 43). At the end of the pro-B cell stage, Bcl-2 is down- 
modulated  (23).  Most  of these  B  cell precursors  will  die 
during the  transition to  pre-B  cells (4,  5)  with  survival of 
those B  cell precursors bearing a  functional pre-B  cell re- 
ceptor complex  (50,  51).  Because Bcl-x  L expression is in- 
duced in pre-B cells, it may serve as a survival signal for the 
small population ofpre-B cells that successfully complete a 
productive rearrangement of their IgG and IgL gene. Later 
in development, both Bcl-2 and Bcl-x  L are downregulated 
in immature IgM+IgD -  cells (23).  Deletion of developing 
B  cells bearing self-reactive IgM receptors occurs at the im- 
mature B  cell stage (52-54).  Thus,  downregulation of both 
Bcl-2 and Bcl-x  L may facilitate the elimination ofautoreac- 
tire B  cells by making the  cells more  vulnerable to  death 
signals  associated with  negative  selection.  At  the  mature 
stage, B  cells express Bcl-2 but not Bcl-x  L (23).  Thus,  Bcl-2 
induction at the mature B  cell stage appears to represent a 
developmental switch involved in the selection and main- 
tenance of peripheral B  cells. The continuous expression of 
Bcl-2  is critical for mature  B  cells since mice  deficient in 
Bcl-2  are  unable  to  maintain  peripheral lymphocytes  (24, 
25). A  very similar pattern of regulated expression for Bcl-XL 
has been observed during T  cell development (55, 56). The 
expression  of Bcl-x  is  the  highest  in  CD4+CD8 +  thy- 
mocytes  and  downregulated in  mature  T  cells.  Thus,  the 
regulation of bcl-x  is conserved in  both  T  and B  cell lin- 
eages. 
It is intriguing that Bcl-2 and Bcl-XL, two structurally re- 
lated proteins  that  exhibit similar function,  are  differently 
regulated during B  cell development.  A  possible explana- 
tion  is  that  Bcl-2  and  Bcl-xe  differ  in  their  ability  to 
counter death signals generated at specific stages during de- 
velopment.  Bcl-2  and  Bcl-x  L share  remarkable  structural 
homology and  localize to  identical intracellular sites,  sug- 
gesting that they inhibit cell death by a similar biochemical 
mechanism  (29, 57).  However, it has been recently shown 
that Bcl-2 and Bcl-x  t  interact differentially with  some  in- 
tracellular targets  in  vivo  (58  and  see  below).  Thus,  it  is 
possible that Bcl-2 and Bcl-x  L differ in a  subtle manner in 
their  functional  ability to  prevent  cell  death.  Consistent 
with  this possibility is the  observation that Bcl-x  L is more 
efficient than Bcl-2 in protecting the immature B  cell line 
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apeutic  agents  (41).  The  antiapoptotic functions  of Bcl-2 
and Bcl-x  r are controlled in part by several interacting pro- 
teins  (58-60),  one  of which  (Bad)  exhibits  a  differential 
ability to heterodimerize with Bcl-2 and Bcl-xr (58). Thus, 
another possibility is that the expression of the interacting 
partners of Bcl-2 and Bcl-x  r is differentially regulated dur- 
ing  B  cell  development.  In  this  scenario,  developmental 
regulation of Bcl-2 and Bcl-xr could reflect differential re- 
quirements  for  complexes  between  Bcl-2  or  Bcl-xL  and 
their interacting partners to perform specific functions dur- 
ing B cell development. 
The signals  that govern Bcl-x  L expression during B  cell 
development remain  to  be  estabhshed.  Because  Bcl-x  L is 
upregulated at the pre-B cell stage, it is possible that signal- 
ing through the pre-B cell receptor complex is involved in 
Bcl-x  L regulation. Mutant mice lacking a functional pre-B 
cell  receptor  complex display a  block in  B  cell  develop- 
ment that  coincides  with  the  massive loss  of precursor B 
cells in normal mice (13).  Thus, it has been postulated that 
the pre-B cell receptor complex transduces signals  that re- 
sult in enhanced survival ofpre-B cells  (14,  15).  A  candi- 
date signal is Bcl-XL since it is upregulated at the pre-B cell 
stage of development and promotes the survival of devel- 
oping B cells. 
Cellular  activation  induces  intracellular  signals  such  as 
c-myc that are involved in both proliferation and cell death 
(61,  62). In B lymphocytes, cross-hnking with anti-IgM or 
anti-IgD induces cell proliferation and ultimately cell death 
(33,  63).  In mature  B  cells,  our studies  demonstrate  that 
Bcl-x  L is upregulated by cross-linking of IgM receptors and 
presumably  by  antigen-IgM  interactions.  This  notion  is 
supported by the  recent  observation that Bcl-x protein is 
expressed  in  proliferating  B  cells  of the  germinal  center 
(45),  arguing  that  Bcl-x  L is  upregulated  during  antigen- 
driven B  cell activation in vivo. Similarly, Bcl-XL was in- 
duced  after  the  CD40-CD40L  interaction,  a  signaling 
pathway known to dehver survival signals to mature B cells 
(64).  As with B  cells,  Bcl-x  r  can be induced  after cellular 
activation in peripheral T  cells (65,  66). Thus, under physi- 
ological  situations,  induction  of Bcl-xr  in  Bcl-2-positive 
mature B and T  cells may serve as a mechanism to counter 
more effectively the death signals  associated with activation 
and prohferation (61, 62). Consistent with this hypothesis is 
our observation that accumulation of B  cells in the animal 
and B lymphocyte survival in vitro was further increased by 
simultaneous expression of bd-xL and bd-2 transgenes. Fur- 
thermore, combined overexpression of  both Bcl-2 and Bcl- 
x L in the absence ofT cell costimulatory function protected 
mature B  cells  from anti-IgD-induced apoptosis more ef- 
fectively than either protein alone. This indicates that Bcl-2 
and Bcl-x  L can function as autonomous survival proteins in 
B lymphocytes. Under our experimental conditions, coex- 
pression  of Bcl-2  and Bcl-xr only partially protected pe- 
ripheral B cells from anti-igD-induced cell death, presum- 
ably because of the powerful cell death signal provided by 
the high afl%ity anti-IgD antibody (33).  The increased sur- 
vival of B  cell expressing both Bcl-2 and Bcl-xr could be 
explained by a gene dose effect, implying that resistance to 
cell death is determined by the relative levels of apoptosis- 
inhibitory proteins. Preliminary results obtained in our lab- 
oratory favor this hypothesis since B cells from double bd-2/ 
bd-2 transgenic mice exhibit in vitro survival greater than 
heterozygous bd-2 transgenic mice and sim~ilar to that ofbcl- 
2/bcl-x  L transgenic animals (Grillot, D., R. Merino, and G. 
Nufiez,  unpublished  observation).  Alternatively,  the  in- 
creased survival could be explained by a specific coopera- 
tion between Bcl-2 and Bcl-xr. Regardless of the mecha- 
nism,  our  studies  suggest  that  for  certain  death  stimuli, 
particularly  those  associated  with  cellular  activation,  coex- 
pression of Bcl-2  and Bcl-x  L may prove critical in  deter- 
mining the fate of certain populations of B cells. 
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